Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2022 | Promising future for cholangiocarcinoma diagnosis and treatment

Lorenza Rimassa • 28 Jun 2022
ESMO WCGIC 2022
Bile Duct Cancer Gastrointestinal Cancer

Lorenza Rimassa, MD, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy, discusses recent positive trials of immunotherapy plus chemotherapy for patients with cholangiocarcinoma, as well as developments in targeted therapies and the advent of molecular profiling. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

More from Lorenza Rimassa

0:51
EMERALD-1 trial: improved PFS w/ durvalumab + bevacizumab + TACE vs TACE in hepatocellular carcinoma
Lorenza Rimassa • 19 Jan 2024
1:15
MONTBLANC: sequential or up-front durvalumab, tremelimumab, + bevacizumab in unresectable HCC
Lorenza Rimassa • 19 Jan 2024
0:41
Therapeutic challenges in HCC: individualizing treatment decisions
Lorenza Rimassa • 20 Jan 2024
0:33
Challenges in implementing first-line triplet therapies in patients with HCC
Lorenza Rimassa • 19 Jan 2024

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals